Podrobno

Položaj OVSE v mednarodnih odnosih : dileme in predlogi reform
ID Zajc, Tomaž (Avtor), ID Bebler, Anton (Mentor) Več o mentorju... Povezava se odpre v novem oknu

URLURL - Predstavitvena datoteka, za dostop obiščite http://dk.fdv.uni-lj.si/diplomska/pdfs/zajc-tomaz.pdf Povezava se odpre v novem oknu

Jezik:Slovenski jezik
Vrsta gradiva:Diplomsko delo
Tipologija:2.11 - Diplomsko delo
Organizacija:FDV - Fakulteta za družbene vede
Kraj izida:Ljubljana
Založnik:[T. Zajc]
Leto izida:2010
Št. strani:82 f.
PID:20.500.12556/RUL-19249 Povezava se odpre v novem oknu
UDK:341.1+341.217:351.78(043.2)
COBISS.SI-ID:29861725 Povezava se odpre v novem oknu
Datum objave v RUL:11.07.2014
Število ogledov:1814
Število prenosov:156
Metapodatki:XML DC-XML DC-RDF
:
ZAJC, Tomaž, 2010, Položaj OVSE v mednarodnih odnosih : dileme in predlogi reform [na spletu]. Diplomsko delo. Ljubljana : T. Zajc. [Dostopano 30 marec 2025]. Pridobljeno s: http://dk.fdv.uni-lj.si/diplomska/pdfs/zajc-tomaz.pdf
Kopiraj citat
Objavi na:Bookmark and Share

Podobna dela

Podobna dela v RUL:
  1. Systematic review and meta-analysis of observational studies evaluating treatment outcomes in patients with metastatic non-small-cell lung cancer on first-line immune checkpoint inhibitors therapy
  2. Description of adverse event of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer treated at the University Clinic Golnik
  3. Effectivness and safety of immunotherapy in patients with advanced non-small cell lung cancer in second line treatment at the University Clinic Golnik
  4. Evaluation of possible pembrolizumab dosing regimen racionalisation in advanced non-small cell lung cancer
  5. ǂThe ǂpotential of immunotherapies in the treatment of lung cancer
Podobna dela v drugih slovenskih zbirkah:
  1. ǂThe ǂrole of immune checkpoint inhibitors in the treatment of cancer of unknown origin
  2. Trans-esophageal endobronchial ultrasound-guided needle aspiration (EUS-B-NA)
  3. Febrile neutropenia and grade 3/4 neutropenia in daily practice of adjuvant chemotherapy for non-small-cell lung cancer
  4. Advances in the therapy with immune-check point inhibitors (ICI) in non-small cell lung cancer (NSCLC) in 2022
  5. Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy

Nazaj